ストックスクリーナーアプリを入手
31.52
0.04%
0.0667
前日終値:
$31.45
開ける：
$31.29
24時間の取引高:
1.03M
Relative Volume:
0.49
時価総額：
$4.55B
収益：
-
当期純損益:
$-507.65M
株価収益率:
-6.8515
EPS:
-4.6
ネットキャッシュフロー:
$-616.24M
1週間 パフォーマンス:
-11.10%
1か月 パフォーマンス:
+2.15%
6か月 パフォーマンス:
-70.51%
1年 パフォーマンス:
-52.02%
1日の値動き範囲:
$31.29
$33.47
1週間の範囲:
$28.09
$35.56
52週間の値動き範囲:
$27.66
$121.06
Vaxcyte Inc Stock (PCVX) Company Profile
名前
Vaxcyte Inc
セクター
電話
650-837-0111
住所
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
PCVX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PCVX
Vaxcyte Inc
|
31.53 | 4.55B | 0 | -507.65M | -616.24M | -4.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.75 | 128.25B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
538.08 | 63.70B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
550.39 | 39.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.06 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.02 | 27.58B | 3.81B | -644.79M | -669.77M | -6.24 |
Vaxcyte Inc Stock (PCVX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-22 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-12-20 | 開始されました | Goldman | Buy |
| 2023-12-07 | 開始されました | Mizuho | Buy |
| 2023-04-18 | 開始されました | TD Cowen | Outperform |
| 2023-01-03 | 繰り返されました | Needham | Buy |
| 2022-12-15 | 開始されました | Guggenheim | Buy |
| 2022-11-17 | 開始されました | BTIG Research | Buy |
| 2021-12-29 | 再開されました | Jefferies | Buy |
| 2021-06-24 | 再開されました | Jefferies | Buy |
| 2020-07-07 | 開始されました | BofA Securities | Buy |
| 2020-07-07 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-07-07 | 開始されました | Needham | Buy |
すべてを表示
Vaxcyte Inc (PCVX) 最新ニュース
Is Vaxcyte, Inc. (PCVX) The Best Stock That Will Bounce Back? - msn.com
Vaxcyte, Inc. Reports Q1 2025 Financial Results - TipRanks
Decoding Vaxcyte Inc (PCVX): A Strategic SWOT Insight - GuruFocus
Vaxcyte (PCVX) Advances Pneumococcal Vaccine Development | PCVX Stock News - GuruFocus
Vaxcyte Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Vaxcyte Inc Reports Q1 2025 EPS of -$1.04, Beating Estimates; Net Loss Widens to $140.7 Million - GuruFocus
Vaxcyte (PCVX) Stock Price, News & Analysis - MarketBeat
Vaxcyte appoints new independent director - Investing.com Australia
Vaxcyte appoints new independent director By Investing.com - Investing.com South Africa
Vaxcyte (PCVX) Welcomes Former Sanofi CEO to Board of Directors | PCVX Stock News - GuruFocus
Vaxcyte (PCVX) Welcomes Former Sanofi CEO to Board of Directors - GuruFocus
Vaxcyte Appoints Dr. Olivier Brandicourt to Board - TipRanks
Vaxcyte adds former Sanofi CEO to its board - Investing.com
Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors | PCVX Stock News - GuruFocus
Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors - The Manila Times
Is Vaxcyte, Inc. (PCVX) the Best Oversold NASDAQ Stock to Buy Right Now? - Yahoo Finance
US Stocks Dip As Investors Eye Trump's Tariff Announcements - Finimize
PCVXVaxcyte, Inc. Latest Stock News & Market Updates - Stock Titan
James T. Wassil ’99G ’05G of Vaxcyte, Inc. Named Lehigh’s 2025 Graduate Commencement and Doctoral Hooding Ceremony Speaker - Lehigh University
Vaxcyte (PCVX) Gains Attention with Overweight Rating Amid Marke - GuruFocus
Vaxcyte (PCVX) Sees Surge in Investor Interest Amid Biotech Buzz - GuruFocus
Vaxcyte (PCVX) Sees Surge in Investor Interest Amid Biotech Buzz | PCVX Stock News - GuruFocus
Commit To Buy Vaxcyte At $20, Earn 14.7% Annualized Using Options - Nasdaq
TD Cowen Keeps Their Buy Rating on Vaxcyte (PCVX) - The Globe and Mail
When the Price of (PCVX) Talks, People Listen - news.stocktradersdaily.com
2 ‘Strong Buy’ Growth Stocks That Could Gain More Than 340% - The Globe and Mail
Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Vaxcyte Stock Plummets 56% in a Month: Here's the Reason - MSN
Vaxcyte Stock Plummets: What’s Next? - timothysykes.com
Vaxcyte, Inc. (PCVX): Billionaire Stanley Druckenmiller’s Top Stock Pick with Huge Upside Potential - Insider Monkey
Vaxcyte stock plunges to 52-week low at $29.53 amid market challenges - Investing.com India
Vaxcyte stock plunges to 52-week low at $29.53 amid market challenges By Investing.com - Investing.com South Africa
Vaxcyte (NASDAQ:PCVX) Price Target Lowered to $137.00 at Bank of America - MarketBeat
InvestingPro Fair Value model correctly predicted Vaxcyte’s decline By Investing.com - Investing.com UK
Vaxcyte (NASDAQ:PCVX) Given New $137.00 Price Target at Bank of America - Defense World
(PCVX) Investment Analysis - news.stocktradersdaily.com
Vaxcyte (PCVX) Stock Falls 45% Despite Positive Vaccine Trial Re - GuruFocus
Vaxcyte ‘narrow’ misses in Phase 2 likely to be ok in Phase 3, says Evercore ISI - Yahoo Finance
BofA lowers Vaxcyte price target, says selloff after infant data ‘overdone’ - TipRanks
Ulta Beauty To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Vaxcyte stock sinks despite Phase II IPD vaccine trial success - Yahoo Finance
Vaxcyte stock up on results from mid-stage trial of its pneumococcal vaccine - MSN
Vaxcyte’s Promising Vaccine Potential and Market Expansion Drive Buy Rating - TipRanks
Goldman Sachs cuts Vaxcyte stock price target to $100 - Investing.com
Vaxcyte Inc (PCVX) 財務データ
収益
当期純利益
現金流量
EPS
Vaxcyte Inc (PCVX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| GUGGENHIME ANDREW | PRESIDENT AND CFO |
Apr 07 '25 |
Option Exercise |
20.93 |
4,777 |
99,983 |
131,950 |
| PICKERING GRANT | CHIEF EXECUTIVE OFFICER |
Apr 04 '25 |
Option Exercise |
8.96 |
20,533 |
183,888 |
518,775 |
| Eydelman Mikhail | SVP, GEN COUNSEL & CORP SEC |
Mar 05 '25 |
Option Exercise |
21.41 |
5,000 |
107,050 |
46,620 |
| Eydelman Mikhail | SVP, GEN COUNSEL & CORP SEC |
Mar 05 '25 |
Sale |
70.74 |
5,000 |
353,699 |
41,620 |
2.11%
0.83%
大文字化:
|
ボリューム (24 時間):